Prosecution Insights
Last updated: April 19, 2026

Inhibrx Biosciences Inc.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18451025 NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF MELCHIOR, JAMES RYLAND 1644 Non-Final OA Aug 16, 2023
18264475 Formulations of DR5 Binding Polypeptides CESARE, JOSEPH DAVID 1675 Non-Final OA Aug 07, 2023
18002613 Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof PATTERSON, SARAH COOPER 1675 Non-Final OA Dec 20, 2022
17418458 Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof EDGINGTONGIORDANO, FRANCESCA 1643 Final Rejection Jun 25, 2021

Managing Inhibrx Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month